Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo

NCT02205541 is registered in ClinicalTrials.gov with University Hospital, Toulouse as lead sponsor.

NCT NCT02205541
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02205541 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo
Lead sponsor
University Hospital, Toulouse
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2015
Completion date
June 30, 2018
Enrollment
100 (actual)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

hemolytic uremic syndrome of childhood